A reversed-phase HPLC method to determine total plasma warfarin was developed and validated.
INTRODUCTION
Owing to its cheaper cost, warfarin is by far the most popular oral anticoagulant for treatment of various types of thromboembolism disorders even when compared to other novel oral anticoagulants that has been demonstrated to be noninferior and have less adverse effects than warfarin (Lippi et al., 2017 , Lippi and Favaloro, 2015 , Looi et al., 2017 ). However, due to its narrow therapeutic window and significant intra-and inter-individual dosing variabilities, the administration of warfarin requires extensive knowledge of the drug's pharmacokinetics and pharmacodynamics (Winkler, 2019) . Patients who are already on warfarin treatment must be regularly monitored to avoid adverse effects or suboptimal dosing. The variability in warfarin dosing is often correlated with polymorphisms in the cytochrome P450 2C9 gene (CYP2C9) and in the vitamin K epoxide reductase complex subunit 1 gene (VKORC1) (Carlquist et al., 2006 , Chua et al., 2014 , which are reported to be responsible for the synthesis of enzymes that metabolize warfarin or involved ASM Science Journal, Volume 12, 2019 2 in the cycling of vitamin K during the coagulation process, respectively.
To correlate warfarin dosing with factors that affect its variability in plasma concentrations, the determination of plasma warfarin levels is important. Some studies utilising gas chromatography (GC) to quantify warfarin levels in biological samples and pharmaceutical products (Pommier et al., 1994 In this study, we developed a new HPLC method to measure plasma warfarin levels using a simple UV detector and a simple liquid-liquid extraction (LLE) method. LLE was used because it has been reported to be more reproducible than non-automated solid phase extraction (Shintani, 2013) , and in our study, it utilised only small amounts of organic solvents following a post-extraction spiked internal standard method. The method was successfully validated and used in the determination of the pharmacokinetics parameters of healthy volunteers.
II. METHODOLOGY

A. Apparatus and chemicals
Warfarin standard was purchased from US Pharmacopeia 
B. Preparation of Standard Solutions
Warfarin working standard solutions at 1, 8, 15, 35, 45 and 60µg/mL were prepared fresh daily by further dilution of their stock solutions (1000g/mL) with ACN. A working standard solution of the internal standard phenylbutazone was prepared fresh daily at 10g/mL by further diluting its stock solution (100g/mL) with ACN. The amlodipine, aspirin, atenolol, atorvastatin, digoxin, enalapril, frusemide, pravastatin and propranolol working standard solutions that were used in the specificity test were prepared separately at 100µg/mL.
C. Sample Preparation and Extraction
Plasma standards were prepared in duplicate by spiking 
B. Extraction Recoveries
The percentage recoveries of warfarin by peak area ratio and slope ratio were above 80% when investigated over the range of 0.1 -6.0µg/mL (Tables 1 and 2 ), which complies with the FDA guideline (CDER, 2001). 
C. Method Performance
The calibration curve of warfarin with six points of concentrations over the range of 0.1 -6.0µg/mL was linear, with a mean correlation coefficient (r 2 ) of 0.992. The lower limit of quantification, defined as five times the baseline noise of a blank injection, was 100ng/mL, while the limit of detection, defined as the lowest concentration that can be identified and differentiated from the baseline noise, was 20ng/mL (CDER, 2001). The QC assays were conducted on three consecutive days. The assays gave good precision and accuracy for both the intraday and interday determinations (Tables 3 and 4) , all of which complied with the FDA requirements. 
D. Specificity Tests
Using the developed LLE method, warfarin was preferentially partitioned from other interfering compounds potentially present in the patients' plasma. Among all of the tested concomitant drugs, only the aspirin, frusemide, pravastatin and propranolol peaks were eluted within 14 min, while the atenolol, atorvastatin, amlodipine, enalapril and digoxin peaks were not eluted (Table 5 ). However, all of the eluted peaks were fully resolved from the warfarin and phenylbutazone peaks and did not interfere with warfarin quantification. 
E. Stability
The stability tests indicated that warfarin remained stable in plasma even after three months of storage ( 
F. Application of the Method
The validated HPLC method was successfully applied for the determination of pharmacokinetics data in four healthy
Malaysian subjects (Table 6 ). In our investigation, however, the height of the phenylbutazone peak was much lower than that of the warfarin peak, giving a higher peak area ratio of warfarin to phenylbutazone. When the peak area ratio was applied to the percentage recovery formula, a high but false percentage recovery was produced. To avoid incorrect quantification, the peak area ratios were obtained using a post-extraction spiked internal standard method in which the internal warfarin standard was added to the sample only following the extraction procedure. The post-extraction spiked internal standard method has been reported to have a similar analytical bias as the pre-extraction spiked internal standard method (Reagen et al., 2008) and was also successfully employed by Jin et al. (2006) in the measurement of serum warfarin levels.
Our study is the first to report on the pharmacokinetics parameters of warfarin among Malaysian subjects. When the pharmacokinetics parameters were compared with those reported from previous studies, the Cmax was found to be lower, which could be attributed to the lower dose administered when compared to a study conducted by Uno 
